论文部分内容阅读
目的:观察降脂通脉胶囊联合依折麦布片治疗高脂血症的临床疗效。方法:选取本院收治的90例高脂血症患者作为研究对象,按患者病历ID号末位数字奇偶随机分为对照组和治疗组各45例,2组均给予控制血压、血糖等基础治疗,疗程均为4周。对照组在此用药基础上给予依折麦布片治疗,治疗组在对照组用药基础上加用降脂通脉胶囊治疗。观察2组临床疗效及不良反应发生情况,比较2组治疗前后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)等血脂指标的变化。结果:总有效率对照组为68.9%,低于治疗组的93.3%,2组比较,差异有统计学意义(P<0.05)。治疗前2组TC、TG、LDL-C及HDL-C比较,差异均无统计学意义(P>0.05)。治疗后,2组各项血脂指标均较治疗前改善,差异均有统计学意义(P<0.05),治疗组各项血脂指标的改善程度均优于对照组,差异均有统计学意义(P<0.05)。治疗期间,2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:降脂通脉胶囊联合依折麦布片治疗高脂血症,可显著改善患者的血脂,提高临床疗效。
Objective: To observe the clinical efficacy of Jiangzhitongmai capsule combined with Ezekibu tablet in the treatment of hyperlipidemia. Methods: Totally 90 patients with hyperlipidemia admitted to our hospital were enrolled in this study. According to the last digit of patients’ medical records ID numbers, 45 cases were randomly divided into control group and treatment group. The two groups were given basic therapy such as blood pressure control and blood glucose control , Treatment are 4 weeks. On the basis of this medication, the control group was treated with Ezeki cloth, and the treatment group was treated with Jiangzhi Tongmai capsule on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were observed. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL- Such as changes in blood lipid indicators. Results: The total effective rate was 68.9% in the control group, which was lower than 93.3% in the treatment group. There was significant difference between the two groups (P <0.05). There was no significant difference in TC, TG, LDL-C and HDL-C between the two groups before treatment (P> 0.05). After treatment, the two groups of lipid indicators improved compared with before treatment, the difference was statistically significant (P <0.05), the treatment group, the improvement of various lipid indicators were better than the control group, the difference was statistically significant (P <0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Jiangzhi Capsule combined with ezetimibe treatment of hyperlipidemia, can significantly improve the patient’s blood lipids and improve clinical efficacy.